Ana Rossi, MD
Nephrology · Atlanta, GANPI 1629277710
Payments from drug & device makers
Across 113 payments — averaging $43.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Calliditas Therapeutics US Inc.$3K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$365
- Veloxis Pharmaceuticals, Inc.$315
- Mallinckrodt Hospital Products Inc.$268
- Intercept Pharmaceuticals, Inc.$254
- Madrigal Pharmaceuticals$171
- plus $901 from 17 others
What the payments were for
- Consulting fees$2,65954%
- Food & beverage$2,23345%
- Education$541%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Calliditas Therapeutics US Inc. | 2 | $2,674 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 19 | $365 |
| Veloxis Pharmaceuticals, Inc. | 7 | $315 |
| Mallinckrodt Hospital Products Inc. | 13 | $268 |
| Intercept Pharmaceuticals, Inc. | 14 | $254 |
| Madrigal Pharmaceuticals | 7 | $171 |
| AstraZeneca(2 entities) | 8 | $157 |
| Novartis | 5 | $132 |
| Astellas Pharma US Inc | 5 | $100 |
| AbbVie | 4 | $80 |
| Ipsen Biopharmaceuticals, Inc | 4 | $68 |
| Travere Therapeutics, Inc. | 11 | $67 |
| ANI Pharmaceuticals, Inc. | 2 | $47 |
| Sanofi-aventis U.S. LLC | 2 | $46 |
| Orphalan Inc | 2 | $39 |
| Pfizer | 1 | $28 |
| Novo Nordisk | 1 | $27 |
| Azurity Pharmaceuticals, Inc. | 1 | $24 |
| Merck | 1 | $22 |
| Invivyd Inc | 1 | $20 |
| Alnylam Pharmaceuticals Inc. | 1 | $19 |
| Melinta Therapeutics, LLC | 1 | $18 |
| Lemaitre Vascular, Inc. | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TARPEYO$2,659
How this compares
$4,947 in reported general payments places this provider in the 70th percentile of 388 nephrology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Atovaquone | 53 | $24,815 |
| Valganciclovir Hcl | 71 | $21,259 |
| VemlidyTenofovir Alafenamide | 11 | $16,124 |
| Nifedipine ErNifedipine | 44 | $1,111 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 74 | $490 |
| Hydralazine Hcl | 31 | $378 |
| Tamsulosin Hcl | 34 | $306 |
| Pantoprazole Sodium | 36 | $253 |
| Prednisone | 61 | $227 |
| Carvedilol | 35 | $210 |
| Losartan Potassium | 13 | $193 |
| Acyclovir | 14 | $188 |
| Amlodipine Besylate | 27 | $115 |
| Clonidine Hcl | 16 | $79 |
| Ciprofloxacin Hcl | 11 | $62 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Atlanta
- Frederic Rahbari OskouiAtlanta$1.5M
- Stuart HandelsmanAtlanta$711K
- Sheldon ShoreAtlanta$474K
- Elizabeth NguyenAtlanta$465K
- William OneillAtlanta$281K
- Janice LeaAtlanta$241K
- Frita FisherAtlanta$220K
- Haimanot WasseAtlanta$194K
- Christina KleinAtlanta$137K
- Mary MuonekeAtlanta$119K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.